Edit |   |
Antigenic Specificity | 14-3-3 (N19) |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | mouse, rat, human |
Isotype | n/a |
Format | unconjugated |
Size | 0.2 mg |
Concentration | 0.200 mg/ml |
Applications | Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC) Paraffin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: Mouse, rat, and human 14-3-3, broadly reactive among the 14-3-3 family (recognizes alpha, beta, theta, and zeta/delta). 14-3-3 family of proteins is composed of seven isotypes, beta, gamma, zeta, epsilon, tau, eta, and sigma, that play critical roles in cell signaling events that control cell cycle progression, transcriptional alterations, and apoptosis (1-4). 14-3-3 proteins were the first signaling molecules to be identified as specific phosphoserine/threonine binding proteins (1). 14-3-3 can serve as a direct regulator of its target by altering the function of the protein (3). 14-3-3 protein targets include the signalling intermediates Raf, MEKK, PI-3 kinase and IRS-1, cell cycle proteins CDK2, Wee1, and Cdc25, and apoptosis |
Immunogen | Immunogen: Synthetic peptide mapping to the amino terminal domain of human 14-3-3. |
Other Names | n/a |
Gene, Accession # | [14-3-3] |
Catalog # | MBS440071 |
Price | $240 |
Order / More Info | 14-3-3 (N19) Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Yaffe MB. 2002. How do 14-3-3 proteins work?- - Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett. 513(1):53-57.2. Liu MY, Cai S, Espejo A, Bedford MT, Walker CL. 2002. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation sites. Cancer Res. 62(22): 6475-6480.3. Tzivion G, Shen YH, Zhu J. 2001. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene 20(44):6331-6338.4. Fu H, Subramanian RR, Masters SC. 2000. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 40:617-647. |